the actual benefit of PHOTOFRIN 75 mg, powder for solution for injection is low in the indication “Treatment of recurrent non-small cell lung cancer or oesophageal cancer that has had previous locoregional treatment”.
Clinical Added Value
no clinical added value
Based on the current data, PHOTOFRIN does not provide any improvement in actual benefit (level V, non-existent) compared with the currently available therapies in the treatment of recurrent non-small cell lung cancer or oesophageal cancer.
Listen
